Well it is May 2025.
A year ago they got phase 2 SCI funding from the DOD and yet nothing..
Roughly a year and half ago they went into tier 3 NIH HEAL program for IND submission/phase 1 enablement of their premier gabakine..
They should have heard or be hearing soon about the SBIR grant for epilepsy..
They reportedly are keeping up with missing filing work, just need audited yet...
We are 4+ months removed from information in a shareholder letter that included 2025 goals of acquiring funding for SEC filing and to conduct research, initiate the phase 2 SCI, submit for more grant funding for their ampakine platform, they also mentioned something about a proposal for the OSA program, and also various maturing strategic deals with the goal of AT LEAST one inked this year with logical speculation that one is likely looming to come out of the NIH HEAL program.
All these activities and timelines are being compressed. IMO, when this emerges from the EM there will likely be a continuous stream of updates and activities, deal making, etc, etc.. and a complete transformation of this company/assets and a valuation reset similar to what historically has been seen in numerous pharma stocks with significant assets heading into human clinicals.
Market Data 
Markets 
AI
